Aarti Industries Clarifies Volume Increase, Cites Market-Driven Factors

Aarti Industries has responded to a clarification request regarding an increase in its security’s trading volume. The company stated that it promptly disseminates all required information to the stock exchanges. Aarti Industries confirmed that there are no undisclosed material announcements that would impact the price or volume of its scrip, attributing the recent movement solely to market-driven factors.

Response to Exchange Clarification

Aarti Industries Limited has formally addressed a request for clarification concerning a notable increase in the volume of its securities trading on the exchanges. The company’s communication, dated June 16, 2026, serves as a direct reply to an inquiry received on the same day.

Disclosure Practices

In its response, Aarti Industries reiterated its commitment to timely disclosure. The company stated that it consistently disseminates all information and events requiring disclosure, as mandated by relevant regulations, to the Stock Exchanges. This practice ensures transparency and adherence to regulatory requirements.

No Undisclosed Material Information

Crucially, Aarti Industries clarified that there are no pending announcements or undisclosed information, beyond what has already been shared with the exchange, that could potentially influence the price or trading volume of its shares. The company explicitly stated that all relevant information has been duly disclosed.

Market-Driven Volume Increase

Based on its assessment, Aarti Industries concluded that the observed increase in trading volume for its security is entirely a result of market dynamics. The company emphasized that the movement is absolutely market driven, with no internal factors or undisclosed events contributing to the surge.

The company has requested that this clarification be taken on record.

Source: BSE

Previous Article

Birla Corporation Limited RCCPL Private Limited's Bank Loan Facilities Affirmed with IND AA/Stable Rating

Next Article

Marksans Pharma Ltd. Completes Acquisition of QliniQ B.V.